JP2018536710A - 混合型脂質異常症の治療 - Google Patents

混合型脂質異常症の治療 Download PDF

Info

Publication number
JP2018536710A
JP2018536710A JP2018543283A JP2018543283A JP2018536710A JP 2018536710 A JP2018536710 A JP 2018536710A JP 2018543283 A JP2018543283 A JP 2018543283A JP 2018543283 A JP2018543283 A JP 2018543283A JP 2018536710 A JP2018536710 A JP 2018536710A
Authority
JP
Japan
Prior art keywords
gemcabene
subject
atorvastatin
daily dose
statin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018543283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536710A5 (enExample
Inventor
チャールズ・エル・ビスゲイア
ダニエラ・カルメン・オニチュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MetaVia Inc
Original Assignee
Gemphire Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemphire Therapeutics LLC filed Critical Gemphire Therapeutics LLC
Publication of JP2018536710A publication Critical patent/JP2018536710A/ja
Publication of JP2018536710A5 publication Critical patent/JP2018536710A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
JP2018543283A 2015-11-06 2016-11-07 混合型脂質異常症の治療 Pending JP2018536710A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562252147P 2015-11-06 2015-11-06
US201562252195P 2015-11-06 2015-11-06
US62/252,195 2015-11-06
US62/252,147 2015-11-06
PCT/US2016/060837 WO2017079748A1 (en) 2015-11-06 2016-11-07 Treatment of mixed dyslipidemia

Publications (2)

Publication Number Publication Date
JP2018536710A true JP2018536710A (ja) 2018-12-13
JP2018536710A5 JP2018536710A5 (enExample) 2019-12-19

Family

ID=58663111

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018543283A Pending JP2018536710A (ja) 2015-11-06 2016-11-07 混合型脂質異常症の治療
JP2018543079A Pending JP2018532808A (ja) 2015-11-06 2016-11-07 心血管疾患の処置のためのゲムカベンの組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018543079A Pending JP2018532808A (ja) 2015-11-06 2016-11-07 心血管疾患の処置のためのゲムカベンの組み合わせ

Country Status (16)

Country Link
US (4) US9849104B2 (enExample)
EP (2) EP3370703A4 (enExample)
JP (2) JP2018536710A (enExample)
KR (2) KR20180073597A (enExample)
CN (2) CN108366957A (enExample)
AU (2) AU2016349634A1 (enExample)
BR (2) BR112018007857A2 (enExample)
CA (2) CA3001627A1 (enExample)
HK (2) HK1257929A1 (enExample)
IL (2) IL258819A (enExample)
MA (1) MA43190A (enExample)
MX (2) MX2018005096A (enExample)
PH (1) PH12018500972A1 (enExample)
RU (2) RU2018120599A (enExample)
SG (2) SG10201912754UA (enExample)
WO (2) WO2017079748A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019043880A (ja) * 2017-09-01 2019-03-22 興和株式会社 医薬組成物

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
ES2860423T3 (es) 2014-05-28 2021-10-05 Childrens Hospital Med Ct Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
EP3218349A2 (en) 2014-11-14 2017-09-20 Gemphire Therapeutics Inc. Processes and intermediates for preparing , -dicarboxylic acid-terminated dialkane ethers
MX2018005096A (es) * 2015-11-06 2018-08-15 Gemphire Therapeutics Inc Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular.
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
KR102399254B1 (ko) 2016-09-28 2022-05-17 아이거 바이오파마슈티컬스 인코포레이티드 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물
SG10202104575WA (en) 2016-11-04 2021-06-29 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
CA3045145A1 (en) 2016-12-05 2018-06-14 Children's Hospital Medical Center Colonic organoids and methods of making and using same
US12281334B2 (en) 2017-04-14 2025-04-22 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
EP3612171A4 (en) 2017-04-18 2020-10-21 Gemphire Therapeutics Inc. GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
WO2019074793A1 (en) 2017-10-10 2019-04-18 Children's Hospital Medical Center OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME
CN111315772A (zh) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 抗apoc3抗体及其使用方法
JP2021504479A (ja) * 2017-11-28 2021-02-15 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 非アルコール性脂肪性肝炎の処置のための方法および医薬組成物
US12379372B2 (en) 2017-12-21 2025-08-05 Children's Hospital Medical Center Digitalized human organoids and methods of using same
CA3106634A1 (en) 2018-07-26 2020-01-30 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
CN112823012A (zh) 2018-09-12 2021-05-18 儿童医院医学中心 用于产生造血干细胞及其衍生物的类器官组合物
BR112021005086A2 (pt) 2018-09-18 2021-06-08 1Globe Biomedical Co., Ltd. tratamento para doença hepática gordurosa não alcoólica
EP3863643A4 (en) * 2018-10-12 2022-07-27 Icahn School of Medicine at Mount Sinai Azd3355 (lesogaberan) for treatment and prevention of nonalcoholic steatohepatitis (nash), liver fibrosis, and other liver conditions
JP2022505033A (ja) * 2018-10-18 2022-01-14 ジェムフィアー セラピューティクス インコーポレイテッド ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
US12534709B2 (en) 2019-05-31 2026-01-27 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
CA3141807A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
CN112851660B (zh) * 2019-11-12 2022-03-18 广东药科大学 含有小檗碱的酸-碱加成盐、其制备方法及其作为药物的用途
CN114957119B (zh) * 2022-05-05 2023-06-16 武汉大学中南医院 一种四氢喹啉螺1,3-茚二酮类衍生物及其制备方法与应用
WO2025186785A1 (en) * 2024-03-08 2025-09-12 TECNIMEDE - Sociedade Técnico-medicinal, SA Oral pharmaceutical composition of pitavastatin, method and uses thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508320A (ja) * 1997-12-12 2002-03-19 ワーナー−ランバート・カンパニー スタチン−カルボキシアルキルエーテル配合物
JP2005527553A (ja) * 2002-03-29 2005-09-15 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 自己免疫疾患の治療におけるスタチン類および他の自己免疫調節剤の利用
JP2005538104A (ja) * 2002-07-26 2005-12-15 メルク　シャープ　エンド　ドーム　リミテッド コレステロール吸収阻害剤、ＨＭＧ−ＣｏＡレダクターゼ阻害剤および安定化剤を含有する組成物
JP2006508973A (ja) * 2002-11-15 2006-03-16 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー Ｃｒｐを低下させ、かつ全身性炎症を軽減する方法
JP2006131559A (ja) * 2004-11-05 2006-05-25 Takeda Chem Ind Ltd 含窒素複素環化合物
JP2008533029A (ja) * 2005-03-08 2008-08-21 レリアント ファーマスーティカルズ インコーポレイテッド スタチン及びω−３脂肪酸による治療方法、並びにそれらの複合生成物
JP2009521452A (ja) * 2005-12-21 2009-06-04 シェーリング コーポレイション コレステロール降下剤およびｈ３受容体アンタゴニスト／逆アゴニストを使用する非アルコール性脂肪性肝疾患の処置
JPWO2009151116A1 (ja) * 2008-06-13 2011-11-17 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
JP2013516489A (ja) * 2010-01-08 2013-05-13 アイシス ファーマシューティカルズ， インコーポレーテッド アンジオポエチン様３発現の調節
JP2014509305A (ja) * 2010-12-27 2014-04-17 ミシガン ライフ セラピューティクス リミティッド ライアビリティ カンパニー 膵炎を治療するためのゲムカベンおよび誘導体
JP2015503588A (ja) * 2012-01-06 2015-02-02 ミシガン ライフ セラピューティクス リミティッド ライアビリティ カンパニーＭｉｃｈｉｇａｎ Ｌｉｆｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｌｃ 心血管疾患のリスクを低減する方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT381664B (de) 1984-02-07 1986-11-10 Steyr Daimler Puch Ag Einrichtung zur ueberwachung elektrischer, von einer gesteuerten wechselstromquelle gespeister widerstandsschweissvorgaenge, insbesondere punktschweissungen
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
CA2039763A1 (en) 1990-04-30 1991-10-31 Henry Y. Pan Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
NZ286920A (en) 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
WO1997016187A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine antagonists
WO1997016181A1 (en) 1995-11-03 1997-05-09 University Of Kentucky Method for the intranasal administration of l-dopa prodrugs
EP1017390B1 (en) * 1997-07-31 2007-04-18 Kos Life Sciences, Inc. Coated tablet comprising nicotinic acid or a compound metabolized to nicotinic acid in an extended release form, and a coating containing an hmg-coa reductase inhibitor in an immediate release form
US6861555B2 (en) 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
US20030105154A1 (en) * 2001-10-24 2003-06-05 Bisgaier Charles Larry Statin-carboxyalkylether combinations
US20040229954A1 (en) * 2003-05-16 2004-11-18 Macdougall Diane Elaine Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt
WO2006054308A2 (en) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
US20090186834A1 (en) * 2005-03-24 2009-07-23 Microbia, Inc. Diphenylheterocycle cholesterol absorption inhibitors
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
CN104825397A (zh) * 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
CN101522623B (zh) 2006-08-03 2013-06-12 塔夫茨大学信托人 无潮红烟酸类似物和其使用方法
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
FI20080353A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi erittäin korkean lääkepitoisuuden tabletin valmistamiseksi
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
WO2008124505A2 (en) * 2007-04-05 2008-10-16 Ironwood Pharmaceuticals,Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
US8969514B2 (en) * 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US9307371B2 (en) 2008-01-18 2016-04-05 Verizon Patent And Licensing Inc. Method and system for SMS/MMS messaging to a connected device
RU2010151944A (ru) * 2008-05-20 2012-06-27 Серенис Терапьютикс С.А. (Fr) Ниацин и нспвс для комбинированной терапии
US20120202849A1 (en) 2009-10-12 2012-08-09 Anil Pareek Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
AU2011270719B2 (en) * 2010-06-24 2015-09-24 Arisaph Pharmaceuticals, Inc. Niacin mimetics, and methods of use thereof
TR201005325A2 (tr) * 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Atorvastatin ve aspirin içeren farmasötik formülasyonlar
EP2604256B1 (en) * 2011-12-14 2016-04-13 Hexal AG Multi layer coatings
CN102525942A (zh) * 2012-01-05 2012-07-04 金陵药业股份有限公司 一种阿托伐他汀钙肠溶微丸及其制备方法
CA2942100A1 (en) * 2014-03-20 2015-09-24 Esperion Therapeutics, Inc. Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders
CN104127391B (zh) * 2014-08-05 2016-08-24 李宝齐 一种含有阿托伐他汀钙的固体药物组合物
MX2018005096A (es) * 2015-11-06 2018-08-15 Gemphire Therapeutics Inc Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular.
CN105434391A (zh) * 2016-01-18 2016-03-30 上海蓝心医药科技有限公司 阿托伐他汀钙肠溶片及其制备方法和应用

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508320A (ja) * 1997-12-12 2002-03-19 ワーナー−ランバート・カンパニー スタチン−カルボキシアルキルエーテル配合物
JP2005527553A (ja) * 2002-03-29 2005-09-15 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 自己免疫疾患の治療におけるスタチン類および他の自己免疫調節剤の利用
JP2005538104A (ja) * 2002-07-26 2005-12-15 メルク　シャープ　エンド　ドーム　リミテッド コレステロール吸収阻害剤、ＨＭＧ−ＣｏＡレダクターゼ阻害剤および安定化剤を含有する組成物
JP2006508973A (ja) * 2002-11-15 2006-03-16 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー Ｃｒｐを低下させ、かつ全身性炎症を軽減する方法
JP2006131559A (ja) * 2004-11-05 2006-05-25 Takeda Chem Ind Ltd 含窒素複素環化合物
JP2008533029A (ja) * 2005-03-08 2008-08-21 レリアント ファーマスーティカルズ インコーポレイテッド スタチン及びω−３脂肪酸による治療方法、並びにそれらの複合生成物
JP2009521452A (ja) * 2005-12-21 2009-06-04 シェーリング コーポレイション コレステロール降下剤およびｈ３受容体アンタゴニスト／逆アゴニストを使用する非アルコール性脂肪性肝疾患の処置
JPWO2009151116A1 (ja) * 2008-06-13 2011-11-17 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
JP2013516489A (ja) * 2010-01-08 2013-05-13 アイシス ファーマシューティカルズ， インコーポレーテッド アンジオポエチン様３発現の調節
JP2014509305A (ja) * 2010-12-27 2014-04-17 ミシガン ライフ セラピューティクス リミティッド ライアビリティ カンパニー 膵炎を治療するためのゲムカベンおよび誘導体
JP2015503588A (ja) * 2012-01-06 2015-02-02 ミシガン ライフ セラピューティクス リミティッド ライアビリティ カンパニーＭｉｃｈｉｇａｎ Ｌｉｆｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｌｃ 心血管疾患のリスクを低減する方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS.GOV, JPN6020037925, 28 October 2015 (2015-10-28), ISSN: 0004496550 *
MANDEMA, JAAP W. ET AL., THE AAPS JOURNAL, vol. 7, no. 3, JPN6020037929, 7 October 2005 (2005-10-07), pages 513 - 522, ISSN: 0004496551 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019043880A (ja) * 2017-09-01 2019-03-22 興和株式会社 医薬組成物

Also Published As

Publication number Publication date
IL259133A (en) 2018-06-28
WO2017079755A1 (en) 2017-05-11
JP2018532808A (ja) 2018-11-08
CN108366957A (zh) 2018-08-03
SG10201912754UA (en) 2020-02-27
US20180325825A1 (en) 2018-11-15
AU2016348638A1 (en) 2018-06-07
HK1257929A1 (zh) 2019-11-01
AU2016349634A1 (en) 2018-05-10
KR20180073597A (ko) 2018-07-02
BR112018009238A8 (pt) 2019-02-26
MX2018005540A (es) 2018-11-09
IL258819A (en) 2018-06-28
WO2017079748A1 (en) 2017-05-11
BR112018007857A2 (pt) 2018-10-30
PH12018500972A1 (en) 2018-12-17
RU2018120599A3 (enExample) 2020-03-11
RU2018120599A (ru) 2019-12-09
MA43190A (fr) 2018-09-12
RU2018120726A (ru) 2019-12-09
MX2018005096A (es) 2018-08-15
HK1259458A1 (zh) 2019-11-29
CA3001627A1 (en) 2017-05-11
EP3370713A1 (en) 2018-09-12
BR112018009238A2 (pt) 2018-11-06
US9849104B2 (en) 2017-12-26
US20170172954A1 (en) 2017-06-22
EP3370703A1 (en) 2018-09-12
KR20180073665A (ko) 2018-07-02
EP3370703A4 (en) 2019-06-19
US20170172955A1 (en) 2017-06-22
RU2018120726A3 (enExample) 2019-12-09
CN108348491A (zh) 2018-07-31
CA3000016A1 (en) 2017-05-11
US20180133177A1 (en) 2018-05-17
SG11201803442UA (en) 2018-05-30
US10449154B2 (en) 2019-10-22
EP3370713A4 (en) 2019-10-23

Similar Documents

Publication Publication Date Title
US10449154B2 (en) Treatment of NASH with Gemcabene
Wang et al. Sodium butyrate suppresses angiotensin II-induced hypertension by inhibition of renal (pro) renin receptor and intrarenal renin–angiotensin system
Beltowski et al. Adverse effects of statins-mechanisms and consequences
Bloomfield et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
CN104244956B (zh) 使用环糊精的方法
Tian et al. Ginkgo Biloba Leaf Extract Attenuates Atherosclerosis in Streptozotocin‐Induced Diabetic Apoe‐/‐Mice by Inhibiting Endoplasmic Reticulum Stress Via Restoration of Autophagy through the mTOR Signaling Pathway
US20240148681A1 (en) Fixed dose combinations and formulations comprising etc1002 and one or more statins and methods of treating or reducing the risk of cardiovascular disease
EP3478276B1 (en) Methods for inhibiting conversion of choline to trimethylamine (tma)
CN108601753A (zh) 抑制胆碱向三甲胺(tma)的转化的方法
EP4376832B1 (en) Obicetrapib for use in treating of cardiovascular disease (cvd) in his hyporesponders
Davidson et al. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study
Florentin et al. l‐Carnitine/Simvastatin reduces lipoprotein (a) levels compared with simvastatin monotherapy: a randomized double‐blind placebo‐controlled study
Dujovne et al. Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose‐ranging study
CA3076235C (en) Methods for inhibiting conversion of choline to trimethylamine (tma)
Zhou et al. Treatment of experimental non-alcoholic steatohepatitis by targeting α7 nicotinic acetylcholine receptor-mediated inflammatory responses in mice
JP2021506907A (ja) 高トリグリセライド血症の治療方法
WO2019070677A1 (en) METHODS OF INHIBITING CONVERSION FROM CHOLINE TO TRIMETHYLAMINE (TMA)
CA3076195C (en) Methods for inhibiting conversion of choline to trimethylamine (tma)
HK1256960A1 (en) Treatment of mixed dyslipidemia
Giammanco et al. Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome
Abou-Elghait et al. Ameliorative Effect Of Rosuvastatin On High Fat Diet Induced Nonalcoholic Fatty liver Disease In Adult Male Albino Rats
Juhász et al. Cardiovascular risk factors in newly diagnosed, untreated Hungarian patients with familial hypercholesterolemia
Abate et al. Other than potency, are all statins the same?
HK40032085A (en) Method of using cyclodextrin
BR112020006085B1 (pt) Métodos para inibir a conversão de colina em trimetilamina (tma)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201006

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210511